MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, M E; Ivan, M; Croce, C M; Nephew, K P
March 2011
Oncogene;3/3/2011, Vol. 30 Issue 9, p1082
Academic Journal
Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood mechanisms. To examine a possible role(s) of aberrantly expressed microRNAs (miRNAs) in acquired fulvestrant resistance, we compared antiestrogen-resistant and -sensitive breast cancer cells, revealing the overexpression of miR-221/222 in the SERD-resistant cell lines. Fulvestrant treatment of estradiol (E2)- and fulvestrant-sensitive MCF7 cells resulted in increased expression of endogenous miR-221/222. Ectopic upregulation of miR-221/222 in estrogen receptor-α (ERα)-positive cell lines counteracted the effects of E2 depletion or fulvestrant-induced cell death, thus also conferring hormone-independent growth and fulvestrant resistance. In cells with acquired resistance to fulvestrant, miR-221/222 expression was essential for cell growth and cell cycle progression. To identify possible miR-221/222 targets, miR-221- or miR-222- induced alterations in global gene expression profiles and target gene expression at distinct time points were determined, revealing that miR-221/222 overexpression resulted in deregulation of multiple oncogenic signaling pathways previously associated with drug resistance. Activation of β-catenin by miR-221/222 contributed to estrogen-independent growth and fulvestrant resistance, whereas TGF-β-mediated growth inhibition was repressed by the two miRNAs. This first in-depth investigation into the role of miR-221/222 in acquired fulvestrant resistance, a clinically important problem, demonstrates that these two 'oncomirs' may represent promising therapeutic targets for treating hormone-independent, SERD-resistant breast cancer.


Related Articles

  • The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Yan Ni Loh; Hedditch, Ellen L.; Baker, Laura A.; Jary, Eve; Ward, Robyn L.; Ford, Caroline E. // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Acquired resistance to Tamoxifen remains a critical problem in breast cancer patient treatment, yet the underlying causes of resistance have not been fully elucidated. Abberations in the Wnt signalling pathway have been linked to many human cancers, including breast cancer, and...

  • The future of the new selective estrogen receptor modulators. Palacios, Santiago // Menopause International;Mar2007, Vol. 13 Issue 1, p27 

    Selective estrogen receptor modulators (SERMs) are compounds that display mixed estrogen agonist/antagonist activity. Currently, four SERMs are licensed for clinical use: tamoxifen, toremifene, clomifene and raloxifene. The STAR and RUTH trials have provided useful data about the potential role...

  • Selective Estrogen Receptor Modulators.  // Encyclopedic Reference of Molecular Pharmacology;2004, p844 

    A definition of the term "selective estrogen receptor modulators" is presented. It refers to synthetic compounds with partially agonistic and partially antagonistic estrogenic properties. They inhibit bone resorption through the mechanisms known for estrogens. Selective estrogen receptor...

  • Breast cancer: Reprogramming ER? Alderton, Gemma K. // Nature Reviews Cancer;Feb2012, Vol. 12 Issue 2, p79 

    The article discusses the importance of understanding the components of the transcription factor oestrogen receptor-α (ERα) to effectively target gene selection and improve the treatment of patients with breast cancer. It cites a study that determines and maps ERα chromatin binding via...

  • Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. Giusti, Francesca; Ottanelli, Silva; Masi, Laura; Amedei, Antonietta; Brandi, Maria Luisa; Falchetti, Alberto // Clinical Cases in Mineral & Bone Metabolism;2011, Vol. 8 Issue 1, p37 

    Breast cancer, mostly exhibiting an hormone-dependent pathogenesis, is a commonly diagnosed cancer in females. It is well known that sex steroids favor the process of carcinogenesis of breast tissue and anti-hormonal therapy of breast cancer aims to decrease the action of estrogens on this...

  • The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer. Jaouena, Gerard; Topa, Siden; Vessi�res, Anne; Leclercq, G.; McGlinchey, Michael J. // Current Medicinal Chemistry;Sep2004, Vol. 11 Issue 18, p2505 

    In the overall scheme of the future development of new drugs for the treatment of breast cancer, specially tamoxifen resistant tumours, we have explored the unprecedented use of organometallic SERMs. The initial idea is to enhance the efficacy of the current standard, i.e. tamoxifen, by...

  • Defining the Role of Raloxifene for the Prevention of Breast Cancer. Kalidas, Mamta; Hilsenbeck, Susan; Brown, Powel // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1731 

    Compares the ability of tamoxifen and raloxifene to reduce the incidence of breast cancer in postmenopausal women at high risk of breast cancer. Implication of the study on the decision of the clinicians whether to use tamoxifen or raloxifene for the prevention of breast cancer; Determination of...

  • Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: Current State of Development. Gennari, Luigi; Merlotti, Daniela; Valleggi, Fabrizio; Martini, Giuseppe; Nuti, Ranuccio // Drugs & Aging;2007, Vol. 24 Issue 5, p361 

    Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as estrogen receptor agonists and antagonists. These drugs have been intensively studied over the past decade and have proven to be a highly...

  • More stable, more estrogenic: the SERM-ERα LBD complex. Li Gao; Yaoquan Tu; Eriksson, Leif A. // Journal of Biophysical Chemistry;Aug2011, Vol. 2 Issue 3, p233 

    Many synthetic selective estrogen receptor mo- dulators (SERMs) have been cocrystallized with the human estrogen receptor α ligand binding domain (ERα LBD). Despite stabilizing the same canonical inactive conformation of the LBD, most SERMs display different ligand-dependent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics